RFA-AG-21-019: Alzheimer’s Disease Research Centers (P30 Clinical Trial Not Allowed)
Internal Deadline: Friday, May 15, 2020, noon PT
LOI: August 15, 2020
External Deadline: September 15, 2020
Award Information: Type: Grant
Estimated Number of Awards: NIA intends to commit $30 million in FY 2021 to fund 12 – 15 awards. Future years amounts will depend on annual appropriations.
Anticipated Amount: Applications may request a budget of up to $2 million in direct costs per year.
Submission Process: PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://app.wizehive.com/webform/USCgrants
Materials to submit:
- Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
- CV – (5 pages maximum)
Who May Serve as PI: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
The objectives of the NIA Alzheimer’s Centers Program are to foster highly interactive, cutting-edge Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) research through the following:
- Create an environment that supports innovative research that has a significant impact on the field of dementia research and treatment;
- Provide core services that leverage funding and unique expertise;
- Raise awareness and interest in fundamental, clinical, and translational dementia research at institutions, as well as locally, regionally, and nationally;
- Foster interdisciplinary collaborations, especially in emerging areas of research, to catalyze new ideas and scientific approaches;
- Attract and retain a diverse group of early stage investigators and investigators new to dementia research;
- Promote the translation of scientific discoveries from bench to bedside to community that improve public health and provide an opportunity for feedback, including validation and effectiveness measures;
- Enable bi-directional translation aimed at accelerating the development of effective treatment and prevention for AD patients at all stages of the disease;
- Provide rapid and broad sharing of analytic and research tools, as well as data, as appropriate and as consistent with achieving the goals of the program; and
- Enhance dementia-related research education opportunities for people with dementia, their care partners, students, scientists, and clinicians.
NIA’s support of Alzheimer’s Centers is intended to foster excellence in research across a broad spectrum of scientific and medical concerns relevant to dementia. To facilitate discovery and its translation into direct benefit to people with dementia and the general public, NIA awards ADRCs to institutions that have a critical mass of excellent dementia-relevant scientific research and share the resulting research resources widely in order to have the greatest impact.
Visit our Institutionally Limited Submission webpage for updates and other announcements.